MCID: MLG079
MIFTS: 44

Malignant Pleural Mesothelioma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Malignant Pleural Mesothelioma

MalaCards integrated aliases for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 12 37 15 73
Malignant Mesothelioma of Pleura 12
Pleural Malignant Mesothelioma 55

Classifications:



External Ids:

Disease Ontology 12 DOID:7474
ICD10 33 C45.0
NCIt 50 C7376
KEGG 37 H00015
UMLS 73 C0812413

Summaries for Malignant Pleural Mesothelioma

Disease Ontology : 12 A pleural cancer that has material basis in mesothelium cells.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to mesothelioma, malignant and pleural disease, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Malignant Pleural Mesothelioma is PVT1 (Pvt1 Oncogene). The drugs Alimta and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and endothelial, and related phenotype is normal.

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Related Disease Score Top Affiliating Genes
1 mesothelioma, malignant 31.4 BAP1 CALB2 MET MSLN MUC1 NKX2-1
2 pleural disease 30.6 BAP1 CALB2 MSLN SPP1
3 sarcoma, synovial 30.2 CALB2 MET MUC1
4 lung cancer susceptibility 3 30.1 BIRC5 CALB2 GAS5 MET MSLN MUC1
5 sarcomatoid mesothelioma 30.1 NKX2-1 THBD WT1
6 lung cancer 30.0 BIRC5 GAS5 MET NKX2-1 PVT1 SNHG7
7 renal cell carcinoma, nonpapillary 29.7 GAS5 MET MUC1 NKX2-1 PVT1 WT1
8 pancreatic cancer 29.6 BIRC5 ENSG00000261211 GAS5 MET MSLN MUC1
9 benign mesothelioma 11.2
10 adenocarcinoma 10.4
11 fallopian tube carcinosarcoma 10.3 CALB2 WT1
12 ovarian serous cystadenofibroma 10.3 CALB2 MUC1
13 adenofibroma 10.3 CALB2 MUC1
14 malignant peritoneal mesothelioma 10.3 BIRC5 MUC1
15 small cell cancer of the lung 10.2
16 solid adenocarcinoma with mucin production 10.2 MUC1 NKX2-1
17 peritoneal benign neoplasm 10.2 CALB2 WT1
18 bile duct cystadenocarcinoma 10.2 CALB2 MUC1
19 endosalpingiosis 10.2 MUC1 WT1
20 diffuse peritoneal leiomyomatosis 10.2 CALB2 WT1
21 ovarian small cell carcinoma 10.2 MUC1 WT1
22 venous hemangioma 10.2 CALB2 WT1
23 malignant epithelial mesothelioma 10.2 THBD WT1
24 mucinous bronchioloalveolar adenocarcinoma 10.2 CALB2 MUC1 NKX2-1
25 lymphohistiocytoid mesothelioma 10.2 CALB2 THBD
26 sertoli cell tumor 10.2 CALB2 MUC1 WT1
27 rhabdoid tumor predisposition syndrome 1 10.2 MUC1 SPP1 WT1
28 malignant ovarian surface epithelial-stromal neoplasm 10.2 MSLN MUC1 WT1
29 chordoid glioma 10.2 MUC1 NKX2-1
30 ovary epithelial cancer 10.2 MSLN MUC1 WT1
31 sertoli-leydig cell tumor 10.2 CALB2 MUC1 WT1
32 osteofibrous dysplasia 10.2 MET MUC1 SPP1
33 thymus cancer 10.2 CALB2 MUC1 NKX2-1
34 pneumothorax, primary spontaneous 10.2
35 patulous eustachian tube 10.2
36 pneumothorax 10.2
37 squamous cell carcinoma 10.2
38 hypoxia 10.2
39 pericardium cancer 10.2 CALB2 MSLN THBD
40 mixed germ cell-sex cord neoplasm 10.2 CALB2 WT1
41 desmoplastic small round cell tumor 10.2 MUC1 WT1
42 rete testis adenocarcinoma 10.2 CALB2 NKX2-1 THBD
43 rete testis neoplasm 10.2 CALB2 NKX2-1 THBD
44 papillary carcinoma 10.2 MET MUC1 NKX2-1
45 mucinous ovarian cystadenoma 10.1 CALB2 MUC1
46 ovarian brenner tumor 10.1 CALB2 THBD WT1
47 spindle cell liposarcoma 10.1 CALB2 WT1
48 pancreas adenocarcinoma 10.1 MET MSLN MUC1
49 malignant biphasic mesothelioma 10.1 CALB2 MSLN THBD WT1
50 thyroid cancer, nonmedullary, 1 10.1 GAS5 NKX2-1 PVT1

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to Malignant Pleural Mesothelioma

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:


fatigue, dyspnea, chest pain, chills, malaise

MGI Mouse Phenotypes related to Malignant Pleural Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.23 BIRC5 CALB2 MET MSLN NKX2-1 THBD

Drugs & Therapeutics for Malignant Pleural Mesothelioma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 446556 60843
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
3
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
4
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
7
Hydroxocobalamin Approved Phase 2, Phase 3,Phase 3 13422-51-0 11953898 44475014
8
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3,Phase 3 13422-55-4
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
11
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
12
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
13
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
14
Raltitrexed Approved, Investigational Phase 3,Phase 1,Phase 2 112887-68-0 104758
15
Nintedanib Approved Phase 3,Phase 2 656247-17-5 56843413
16
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
17
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
18
Nivolumab Approved Phase 3,Phase 2 946414-94-4
19
Celecoxib Approved, Investigational Phase 3,Phase 1,Phase 2 169590-42-5 2662
20
Pembrolizumab Approved Phase 2, Phase 3,Phase 3,Phase 1 1374853-91-4
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
22
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 68-19-9 44176380
23
Doxil Approved June 1999 Phase 3,Phase 2 31703
24
Cobalamin Experimental Phase 2, Phase 3,Phase 3 13408-78-1 6438156
25 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 Antiemetics Phase 3,Phase 2,Phase 1
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
30 Alkylating Agents Phase 3,Phase 1,Phase 2
31 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
33 Folate Phase 3,Phase 2,Phase 1,Not Applicable
34 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
35 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Antimetabolites Phase 3,Phase 2,Phase 1
38 Vitamins Phase 2, Phase 3,Phase 3
39 Vitamin B 12 Phase 2, Phase 3,Phase 3
40 Vitamin B12 Phase 2, Phase 3,Phase 3
41 Micronutrients Phase 3,Phase 2
42 Autonomic Agents Phase 3,Phase 2,Phase 1
43 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
44 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
45 BB 1101 Phase 3,Phase 2,Phase 1
46 Trace Elements Phase 3,Phase 2
47 Antiviral Agents Phase 3,Phase 2,Phase 1
48 Immunoglobulins Phase 3,Phase 2,Phase 1
49 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
50 Antibodies Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 201)
# Name Status NCT ID Phase Drugs
1 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
2 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) Completed NCT00128102 Phase 3 vorinostat;Placebo
3 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
4 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
5 Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Completed NCT00004920 Phase 3 cisplatin;raltitrexed
6 Nintedanib (BIBF 1120) in Mesothelioma Completed NCT01907100 Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
7 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
8 Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
9 Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
10 Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
11 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
12 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
13 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Active, not recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
14 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma Not yet recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
15 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma Not yet recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
16 PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Terminated NCT01604005 Phase 3
17 A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
18 Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
19 Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
20 Four Versus Six Cycles of Pemetrexed/Platinum for MPM Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
21 Combination Gene Transfer and Chemotherapy Unknown status NCT01119664 Phase 1, Phase 2 SCH 721015
22 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
23 MPM PDT Phase II Trial Unknown status NCT02153229 Phase 2 Photofrin 2.0 mg/kg
24 A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
25 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
26 A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma Unknown status NCT01649024 Phase 2 Tremelimumab
27 The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma Unknown status NCT01655888 Phase 2 Tremelimumab
28 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
29 Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma Unknown status NCT01281800 Phase 2
30 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Unknown status NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
31 Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
32 Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00386815 Phase 2 pemetrexed;cisplatin
33 Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment Completed NCT01243632 Phase 2 Prolonged 6-hr infusion of gemcitabine
34 A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT01486368 Phase 2 PF-03446962
35 Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00484276 Phase 2 NGR-hTNF
36 Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) Completed NCT02397928 Phase 2 Pemetrexed;Cisplatin or Carboplatin
37 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2 everolimus
38 Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Completed NCT00272558 Phase 2 Carboplatin and Vinorelbine
39 Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma Completed NCT02662504 Phase 2 Adjuvant chemotherapy
40 A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma Completed NCT02347917 Phase 1, Phase 2 BBI608;Pemetrexed;Cisplatin
41 WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy Completed NCT01265433 Phase 2
42 Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) Completed NCT00700336 Phase 1, Phase 2 pemetrexed, cisplatin and CBP501;pemetrexed and cisplatin
43 Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma Completed NCT01112293 Phase 2 GC1008
44 Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM Completed NCT01358084 Phase 2 NGR-hTNF;Placebo
45 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00459862 Phase 2 pazopanib hydrochloride
46 Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00251550 Phase 1, Phase 2 Pemetrexed;Cisplatin
47 Bortezomib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00513877 Phase 2 bortezomib
48 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Completed NCT00243074 Phase 2 cediranib maleate
49 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma Completed NCT00738582 Phase 2 MORAb-009 (Amatuximab);Pemetrexed;Cisplatin
50 Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00227630 Phase 2 cisplatin;pemetrexed disodium

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Genetic Tests for Malignant Pleural Mesothelioma

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

41
Lung, T Cells, Endothelial, Thymus, Testes, Liver, Kidney

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 1375)
# Title Authors Year
1
Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report. ( 30533375 )
2019
2
Correction: Apoptosis by [Pt(O,O'-acac)(I^-acac)(DMS)] requires PKC-I' mediated p53 activation in malignant pleural mesothelioma. ( 29432478 )
2018
3
Expression analysis of High-mobility group box-1 (HMGB1) in histologic samples of malignant pleural mesothelioma. ( 29356044 )
2018
4
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. ( 29362358 )
2018
5
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. ( 29444986 )
2018
6
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. ( 29946373 )
2018
7
PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma. ( 29908324 )
2018
8
Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. ( 29967955 )
2018
9
Current surgical treatment of malignant pleural mesothelioma. ( 29980443 )
2018
10
Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma. ( 29873168 )
2018
11
Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review. ( 29387394 )
2018
12
Radical multimodality therapy for malignant pleural mesothelioma. ( 29309720 )
2018
13
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. ( 29438360 )
2018
14
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. ( 29876617 )
2018
15
Biomarkers in malignant pleural mesothelioma: current status and future directions. ( 29850181 )
2018
16
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival. ( 29413055 )
2018
17
A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol. ( 29853412 )
2018
18
Critical role of the Ror-family of receptor tyrosine kinases in invasion and proliferation of malignant pleural mesothelioma cells. ( 29845703 )
2018
19
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. ( 29931180 )
2018
20
Heterogeneity in Malignant Pleural Mesothelioma. ( 29848954 )
2018
21
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. ( 29346042 )
2018
22
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. ( 29313814 )
2018
23
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. ( 29914087 )
2018
24
The management of malignant pleural mesothelioma in the USA 2004-13-a decade of lost opportunity? ( 29849196 )
2018
25
Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients. ( 29338319 )
2018
26
Variation in incidence trends of malignant pleural mesothelioma in Europe. ( 29437947 )
2018
27
Malignant Pleural Mesothelioma: The Last 8 Years of Experience in Our Area. ( 29804950 )
2018
28
Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania. ( 29400553 )
2018
29
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. ( 29399399 )
2018
30
Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. ( 29921948 )
2018
31
Is there a role for immunotherapy in malignant pleural mesothelioma? ( 29845408 )
2018
32
Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. ( 29935841 )
2018
33
Breast Metastasis from Malignant Pleural Mesothelioma: A Rare Challenging Entity. ( 29935848 )
2018
34
Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience. ( 29367501 )
2018
35
Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma. ( 29742520 )
2018
36
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. ( 29804728 )
2018
37
Proton beam therapy for malignant pleural mesothelioma. ( 29876318 )
2018
38
Malignant Pleural Mesothelioma presenting with Cardiac Tamponade- A Rare Case report and Review of the literature. ( 30294454 )
2018
39
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial. ( 30524880 )
2018
40
Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. ( 30524884 )
2018
41
Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan. ( 30530573 )
2018
42
Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy. ( 30535191 )
2018
43
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. ( 30539198 )
2018
44
BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival. ( 30553477 )
2018
45
Updates in the diagnosis and treatment of malignant pleural mesothelioma. ( 29553973 )
2018
46
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. ( 29575535 )
2018
47
National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma. ( 29576300 )
2018
48
Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study. ( 29587685 )
2018
49
SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. ( 29594241 )
2018
50
Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. ( 29601534 )
2018

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

7 (show all 35)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13406 1 1 2300000 Loss Pleural malignant mesothelioma
2 21839 1 16200000 28000000 Loss Pleural malignant mesothelioma
3 33951 1 50700000 61300000 Amplification Pleural malignant mesothelioma
4 35953 1 69700000 116100000 Loss Pleural malignant mesothelioma
5 35955 1 69700000 116100000 Loss CLCA1 Pleural malignant mesothelioma
6 35957 1 69700000 116100000 Loss CLCA2 Pleural malignant mesothelioma
7 35959 1 69700000 116100000 Loss CLCA3 Pleural malignant mesothelioma
8 35961 1 69700000 116100000 Loss CLCA4 Pleural malignant mesothelioma
9 35963 1 69700000 116100000 Loss COL11A1 Pleural malignant mesothelioma
10 35965 1 69700000 116100000 Loss TGFBR3 Pleural malignant mesothelioma
11 35967 1 69700000 120600000 Loss Pleural malignant mesothelioma
12 37057 1 84900000 107200000 Loss Pleural malignant mesothelioma
13 69953 12 56600000 58100000 Gain Pleural malignant mesothelioma
14 75173 13 17900000 45800000 Loss BRCA2 Pleural malignant mesothelioma
15 85739 14 50900000 107349540 Loss CCNK Pleural malignant mesothelioma
16 85741 14 50900000 107349540 Loss CDKN3 Pleural malignant mesothelioma
17 113646 17 44900000 81195210 Gain ERN1 Pleural malignant mesothelioma
18 113648 17 44900000 81195210 Gain MAP3K3 Pleural malignant mesothelioma
19 113650 17 44900000 81195210 Gain PRKCA Pleural malignant mesothelioma
20 113652 17 44900000 81195210 Gain SMARCD2 Pleural malignant mesothelioma
21 175423 3 39400000 63700000 Loss CACNA2D3 Pleural malignant mesothelioma
22 175425 3 39400000 63700000 Loss CTNNB1 Pleural malignant mesothelioma
23 175427 3 39400000 63700000 Loss MLH1 Pleural malignant mesothelioma
24 175772 3 44100000 44200000 Loss Pleural malignant mesothelioma
25 187515 4 50400000 191154276 Loss Pleural malignant mesothelioma
26 191706 5 1 48400000 Gain Pleural malignant mesothelioma
27 204730 6 114600000 118300000 Loss HDAC2 Pleural malignant mesothelioma
28 204732 6 114600000 118300000 Loss MARCKS Pleural malignant mesothelioma
29 217076 7 1 4500000 Gain Pleural malignant mesothelioma
30 234872 8 139900000 146364022 Gain Pleural malignant mesothelioma
31 250027 9 19900000 25600000 Loss C9orf14 Pleural malignant mesothelioma
32 250030 9 19900000 25600000 Loss CDKN2A Pleural malignant mesothelioma
33 250032 9 19900000 25600000 Loss CDKN2B Pleural malignant mesothelioma
34 250070 9 19900000 33200000 Loss Pleural malignant mesothelioma
35 251885 9 33200000 36300000 Gain Pleural malignant mesothelioma

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for Malignant Pleural Mesothelioma

GO Terms for Malignant Pleural Mesothelioma

Sources for Malignant Pleural Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....